Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway., Anticancer research, 40(9) 4961-4968, 2020.09

Keita Togashi, Masashi Okada, Shuhei Suzuki, Tomomi Sanomachi, Shizuka Seino, Masahiro Yamamoto, Hidetoshi Yamashita, Chifumi Kitanaka

Single Author

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing., Biomedicines, 8(8) , 2020.08

Shuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi, Keita Togashi, Asuka Sugai, Shizuka Seino, Masashi Okada, Takashi Yoshioka, Chifumi Kitanaka

Single Author

Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells., The FEBS journal, 287(10) 2023-2036, 2020.05

Kenta Kuramoto, Masahiro Yamamoto, Shuhei Suzuki, Tomomi Sanomachi, Keita Togashi, Shizuka Seino, Chifumi Kitanaka, Masashi Okada

Single Author

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs., Cancers, 11(10) , 2019.10

Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C, Yamamoto M

Single Author

Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer., Anticancer research, 39(9) 4817-4828, 2019.09

Sanomachi T, Suzuki S, Togashi K, Seino S, Yoshioka T, Kitanaka C, Okada M, Yamamoto M

Single Author

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction., Cancers, 11(7) , 2019.06

Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Yoshioka T, Kitanaka C, Okada M

Single Author

<i>In vitro</i> and <i>in vivo</i> anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile., Oncotarget, 10(37) 3547-3558, 2019.05

Suzuki S, Yamamoto M, Togashi K, Sanomachi T, Sugai A, Seino S, Yoshioka T, Kitanaka C, Okada M

Single Author

AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1., Anticancer research, 39(2) 609-617, 2019.02

Masahiro Yamamoto, Shuhei Suzuki, Keita Togashi, Tomomi Sanomachi, Shizuka Seino, Chifumi Kitanaka, Masashi Okada

Single Author

AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel., Anticancer research, 38(12) 6699-6706, 2018.12

Masahiro Yamamoto, Shuhei Suzuki, Keita Togashi, Tomomi Sanomachi, Shizuka Seino, Chifumi Kitanaka, Masashi Okada

Single Author

AS602801, an Anti-Cancer Stem Cell Drug Candidate, Suppresses Gap-junction Communication Between Lung Cancer Stem Cells and Astrocytes., Anticancer research, 38(9) 5093-5099, 2018.09

Kuramoto K, Yamamoto M, Suzuki S, Sanomachi T, Togashi K, Seino S, Kitanaka C, Okada M

Single Author

AS602801, an Anti-Cancer Stem Cell Drug Candidate, Suppresses Gap-junction Communication Between Lung Cancer Stem Cells and Astrocytes., Anticancer Res, 2018.09

Kuramoto Kenta, Yamamoto Masahiro, Suzuki Shuhei, Sanomachi Tomomi, Togashi Keita, Seino Shizuka, Kitanaka Chifumi, Okada Masashi

Single Author

A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel., Anticancer research, 38(8) 4535-4542, 2018.08

Togashi K, Okada M, Yamamoto M, Suzuki S, Sanomachi T, Seino S, Yamashita H, Kitanaka C

Single Author

Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel, Oncol Rep , 2015.11

Seino M*, Okada M*, Sakaki H, Takeda H, Watarai H, Suzuki S, Seino S, Kuramoto K, Ohta T, Nagase S, Kurachi H, Kitanaka C.

Single Author

Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. , Oncotarget, 2015.01

Shibuya K*, Okada M*, Suzuki S, Seino M, Seino S, Takeda H Kitanaka C.

Single Author

JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. , Oncotarget, 2015.01

Suzuki S*, Okada M*, Shibuya K, Seino M, Sato A, Takeda H, Seino S, Yoshioka T, Kitanaka C.

Single Author

Differential contribution of ROS to resveratrol-induced cell death and loss of self-renewal capacity of ovarian cancer stem cells., Anticancer Res, 2015.01

Seino M*, Okada M*, Shibuya K, Seino S, Suzuki S, Takeda H, Ohta T, Kurachi H, Kitanaka C.

Single Author

Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells. , Anticancer Res, 2014.09

Seino M*, Okada M*, Shibuya K, Seino S, Suzuki S, Ohta T, Kurachi H, Kitanaka C.

Single Author

Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation. , Oncotarget, 2014.07

Okada M, Shibuya K, Sato A, Seino S, Suzuki S, Seino M, Kitanaka C.

Single Author

JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. , Int J Oncol, 2014.02

Okada M, Sato A, Shibuya K, Watanabe E, Seino S, Suzuki S, Seino M, Narita Y, Shibui S, Kayama T, Kitanaka C.

Single Author

Pivotal Role for ROS Activation of p38 MAPK in the Control of Differentiation and Tumor-Initiating Capacity of Glioma-Initiating Cells. , Stem Cell Res, 2014.01

Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Narita Y, Shibui S, Kayama T, Kitanaka C.

Single Author

Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells. , Oncol Rep, 2013.10

Okada M, Shibuya K, Sato A, Seino S, Watanabe E, Suzuki S, Seino M, Kitanaka, C.

Single Author

Glioma-Inisiating Cell Elimination by Metformin Activation of FOXO3 via AMPK. , Stem Cells Translational Medicine, 2012.11

Sato A, Sunayama J, Okada M, Watanabe E, Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T, Kitanaka C

Single Author

DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry., Cellular Signalling, 2012.08

Okada M, Hozumi Y, Tanaka T, Suzuki Y, Yanagida M, Araki Y, Evangelisti C, Yagisawa H, Topham MK, Martelli AM, Goto K

Single Author

Targeting JNK for therapeutic depletion of stem-like glioblastoma cells., Scientific reports, 2012

Matsuda K, Sato A, Okada M, Shibuya K, Seino S, Suzuki K, Watanabe E, Narita Y, Shibui S, Kayama T, Kitanaka C.

Single Author

Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of Merlin., Cancer Res, 2009.05

Okada M, Wang Y, Jang SW, Tang X, Neri LM, Ye K

Single Author

Akt phosphorylation and nuclear phosphoinositides association mediate mRNA export and cell proliferation activities by ALY, Proc Natl Acad Sci U S A, 2008.06

Okada M, Jang SW and Ye K

Single Author

Netrin-1 mediates neuronal survival through PIKE-L interaction with the dependence receptor UNC5B, Nat Cell Biol., 2008.06

Tang X, Jang SW, Okada M, Chan CB, Feng Y, Liu Y, Luo SW, Hong Y, Rama N, Xiong WC, Mehlen P and Ye K

Single Author

Ebp1 association with nucleophosmin/B23 is essential for regulating cell proliferation and suppressing apoptosis., J Biol Chem. , 2007.12

Okada M, Jang SW, and Ye K

Single Author

Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. , Proc Natl Acad Sci U S A, 2007.10

Jang SW, Okada M, Sayeed I, Xiao G, Stein D, Jin P and Ye K

Single Author